

POST-TEST

An Evening with the Investigators: Perspectives on Key Questions and Emerging Research in the Management of Gastrointestinal Cancers — A Special Audio Supplement

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The results of the Phase III PRODIGE 24 trial demonstrated _____ for patients with resected PDAC who received modified FOLFIRINOX versus gemcitabine.
 - a. A significant improvement in disease-free survival
 - b. A significant improvement in overall survival
 - c. Fewer side effects
 - d. All of the above
 - e. Both a and b
2. Patients with mPDAC enrolled on the Phase III NAPOLI-1 trial had a significantly higher _____ with nanoliposomal irinotecan and 5-FU/LV compared to 5-FU/LV alone.
 - a. Progression-free survival
 - b. Overall survival
 - c. Both a and b
3. Results from the Phase III REACH-2 trial presented at ASCO 2018 by Zhu and colleagues _____ a significant improvement in overall survival with ramucirumab versus placebo as second-line treatment in patients with advanced HCC and elevated baseline alpha-fetoprotein.
 - a. Demonstrated
 - b. Did not demonstrate
4. Patients with BRAF mutation-positive mCRC do not respond to treatment with immune checkpoint inhibitors.
 - a. True
 - b. False
5. Which of the following categories reflects the drug class of the agent PEGPH20?
 - a. Anti-PD-1/PD-L1 antibody
 - b. MEK inhibitor
 - c. Recombinant human hyaluronidase enzyme
 - d. Cancer stemness inhibitor
 - e. None of the above
6. Which of the following patients with mCRC do not derive clinical benefit from the addition of EGFR antibodies to chemotherapy?
 - a. Patients with left-sided primary tumors
 - b. Patients with right-sided primary tumors
7. The FDA has approved pembrolizumab for all patients with unresectable or metastatic MSI-high or mismatch repair-deficient solid tumors who have experienced disease progression after prior treatment and who have no satisfactory alternative treatment options.
 - a. True
 - b. False
8. A Phase III trial comparing lenvatinib to sorafenib as first-line treatment for HCC demonstrated _____ with lenvatinib versus sorafenib.
 - a. Noninferiority with respect to overall survival
 - b. Improvement in progression-free survival
 - c. Both a and b
9. The hand-foot skin reaction associated with regorafenib typically occurs _____ in the course of treatment.
 - a. Early
 - b. Late
10. The KEYNOTE-061 study demonstrated a significant improvement in overall survival with pembrolizumab versus paclitaxel for patients with previously treated, advanced gastric or gastroesophageal junction cancer.
 - a. True
 - b. False